Select Content Type
eBooks
Authored By
Visani, Giuseppe
Authored On
Mon, 05/01/2000 - 05:30
Interests
Emergency Medicine
ENT
Surgery
Speciality
Surgery
Emergency Medicine
ENT
Book Detail
Publication Date
Mon, 05/01/2000 - 12:00
Event Data
{"title":"Ear, Nose, and Throat Diseases","subtitle":"With Head and Neck Surgery","e_issn":null,"url":"https:\/\/research.ebsco.com\/c\/tyhpwl\/search\/results?q=AN+4205909&db=nlebk","series":"","edition":"4","author":"Hans Behrbohm-Oliver Kaschke-Tadeus Nawka-Andrew C. Swift","contract_publisher":"Thieme Medical Publishing Inc.","imprint_publisher":"Thieme","pub_year":"2023","interest_area":["ENT"," Emergency Medicine"," Surgery"],"lcc":"RF56","lcsh":"Handbook,Head--surgery,Neck--surgery,Otorhinolaryngologic Diseases,Otorhinolaryngologic Surgical Procedures--method","language":"eng","format":"EPUB,PDF","downloadable":"TRUE","fiction":"FALSE","abridged":"","book_id":"4205909","isbn":"9783136712047","eisbn":"9783131702142","ocn":"1519446215","ddc":"617.5","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Visani, Giuseppe","Subjects":"Cancer chemotherapy, Leukemia, Therapeutics, Immune response","Languages":"English","Published_Date":"2000-05-01","Title_Abbreviations":"Leukemia & Lymphoma","Volume":"37"},"header":{"DbId":"asr","DbLabel":"STM Source","An":"4205909","RelevancyScore":"1279","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"1278.94836425781"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=asr&AN=4205909&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=asr&AN=4205909&authtype=shib&custid=ns346513&group=main&profile=eds"}
Upload Link
https://research.ebsco.com/c/tyhpwl/search/results?q=AN+4205909&db=nlebk
Additional Info
["Visani, Giuseppe","Cancer chemotherapy, Leukemia, Therapeutics, Immune response","English","2000-05-01","Leukemia & Lymphoma","37"]
Description
Examines the efficacy of secondary leukemia chemotherapy. Effect of using a high dose of ara-C on immune resistance; Prognostic factors to be considered for response and disease-free survival following therapy; Observation of a higher incidence of poor prognostic characteristics associated with treatment resistance or failure.
Published Date
Thu, 02/19/2026 - 13:58